优化药物转运体探针鸡尾酒:转运体介导药物相互作用的潜在筛选工具
本研究在30名健康男性受试者中开展随机、开放、单中心、五治疗、五周期交叉试验,将地高辛0.25 mg、呋塞米1 mg、二甲双胍10 mg和瑞舒伐他汀10 mg作为鸡尾酒联合给药,与各药单独给药比较药代动力学。
要点
- 地高辛0.25 mg、呋塞米1 mg、二甲双胍10 mg和瑞舒伐他汀10 mg联合给药无相互药代动力学影响。
- 优化后的鸡尾酒耐受良好,有望用于转运体介导DDI的临床筛选。
核心结论
- 地高辛0.25 mg、呋塞米1 mg、二甲双胍10 mg和瑞舒伐他汀10 mg作为鸡尾酒联合给药时无相互药代动力学相互作用且耐受良好。
- 优化后的鸡尾酒有潜力作为转运体介导药物相互作用临床研究的筛选工具。
研究设计与样本
- 随机、开放、单中心、五治疗、五周期交叉试验,30名健康男性受试者参加。
- 参考治疗为单独给予地高辛0.25 mg、呋塞米1 mg、二甲双胍10 mg和瑞舒伐他汀10 mg,试验治疗为四药联合鸡尾酒。
- 主要药代动力学终点为各探针药的AUC0-tz和Cmax。
主要发现
- 试验/参考的AUC0-tz几何均值比(90%CI)分别为地高辛96.4%(88.2-105.3%)、呋塞米102.6%(93.8-112.3%)、二甲双胍97.5%(93.5-101.6%)、瑞舒伐他汀105.0%(96.4-114.4%),提示无相互作用。
- Cmax及所有鸡尾酒组分的尿液排泄药代动力学参数分析同样提示无DDI。
关键数值与推荐
- 地高辛0.25 mg(P-gp探针)、呋塞米1 mg(OAT1/OAT3探针)、二甲双胍10 mg(OCT2/MATE1/MATE2-K探针)、瑞舒伐他汀10 mg(OATP1B1/OATP1B3/BCRP探针)组成鸡尾酒。
临床怎么用
- 该鸡尾酒方案可用于临床研究中筛查转运体介导的药物相互作用。
- 联合给药时无需因探针药间相互作用而调整各成分剂量。
局限性
- 研究仅纳入健康男性受试者,结果外推至女性、患者人群或其他种族需谨慎。
- 样本量为30名健康男性,属于早期药代动力学研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Previous pharmacokinetic characterization of a transporter probe cocktail containing digoxin (P-gp), furosemide (OAT1, OAT3), metformin (OCT2, MATE1, MATE2-K) and rosuvastatin (OATP1B1, OATP1B3, BCRP) in healthy subjects showed increases in rosuvastatin systemic exposure compared to rosuvastatin alone. In this trial, the doses of metformin and furosemide as putative perpetrators were reduced to eliminate their drug-drug interaction (DDI) with rosuvastatin. METHODS: In a randomized, open-label, single-centre, five-treatment, five-period crossover trial, 30 healthy male subjects received as reference treatments separately 0.25 mg digoxin, 1 mg furosemide, 10 mg metformin and 10 mg rosuvastatin, and as test treatment all four drugs administered together as a cocktail. Primary pharmacokinetic endpoints were AUC0-tz (area under the plasma concentration-time curve from time zero to the last quantifiable concentration) and Cmax (maximum plasma concentration) of each probe drug. RESULTS: Geometric mean ratios and 90% confidence intervals of test (cocktail) to reference (single drug) for AUC0-tz were 96.4% (88.2-105.3%) for digoxin, 102.6% (93.8-112.3%) for furosemide, 97.5% (93.5-101.6%) for metformin and 105.0% (96.4-114.4%) for rosuvastatin, indicating lack of interaction. The same analysis for Cmax and for pharmacokinetic parameters of urinary excretion of all cocktail components also indicated no DDI. CONCLUSIONS: Digoxin (0.25 mg), furosemide (1 mg), metformin (10 mg) and rosuvastatin (10 mg) exhibit no mutual pharmacokinetic interactions and are well tolerated administered as a cocktail. The cocktail is thus optimized and has the potential to be used as a screening tool for clinical investigation of transporter-mediated DDI.
引用
- Stopfer P, Giessmann T, Hohl K, et al. Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions. Br J Clin Pharmacol. 2018. PMID: 29665130. doi:10.1111/bcp.13609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。